Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viatris Inc.

10.17
+0.07000.69%
Post-market: 10.02-0.1516-1.49%19:55 EDT
Volume:5.51M
Turnover:55.91M
Market Cap:11.86B
PE:-3.48
High:10.20
Open:10.09
Low:10.07
Close:10.10
52wk High:13.55
52wk Low:6.85
Shares:1.17B
Float Shares:1.16B
Volume Ratio:0.74
T/O Rate:0.48%
Dividend:0.48
Dividend Rate:4.72%
EPS(TTM):-2.9198
EPS(LYR):-0.5315
ROE:-19.77%
ROA:2.30%
PB:0.76
PE(LYR):-19.14

Loading ...

Viatris Inc. Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Sep 11

Colorado must face Teva's lawsuit over free allergy pen law

Reuters
·
Sep 06

Viatris Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Sep 05

BRIEF-FDA Discontinues Manufacture Of Dymista, Nasal Spray, 137 Ug 50 Ug

Reuters
·
Sep 04

FDA: Discontinuation of Manufacture of Dymista, Nasal Spray, 137 Ug; 50 Ug

THOMSON REUTERS
·
Sep 04

The companies where investors have the highest hopes and dreams have some predictable, and surprising, results

Dow Jones
·
Sep 03

Viatris Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
Aug 30

Viatris Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
Aug 27

Viatris Inc. Files Initial Statement of Beneficial Ownership for Officer Andrew Enrietti

Reuters
·
Aug 20

Press Release: Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Dow Jones
·
Aug 19

Jefferies Adjusts Price Target on Viatris to $14 From $13, Maintains Buy Rating

MT Newswires Live
·
Aug 18

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS

Benzinga_recent_news
·
Aug 17

Viatris Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
Aug 15

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

Reuters
·
Aug 15

Viatris Inc. Files Initial Beneficial Ownership Statement for Director David S. Simmons

Reuters
·
Aug 14

Opus Genetics Q2 2025 Results: Reports Positive Clinical Milestones, No Sales/Revenue or Profit Data Provided

Reuters
·
Aug 14

Theravance Biopharma Reports 31% Increase in Viatris Collaboration Revenue for Q2 2025; YUPELRI Net Sales Rise 22% Year-over-Year

Reuters
·
Aug 13

Viatris Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
Aug 12

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires Live
·
Aug 12

Viatris Inc. Secures FDA Approval for First Generic Iron Sucrose Injection, Marking a Milestone in Treatment for CKD and Iron Deficiency Anemia

Reuters
·
Aug 11